Ever since biosimilar competition to AbbVie Inc.'s Humira (adalimumab) began to hit the US market in early 2023, all eyes have been on the uptake of off-patent rivals, given that the product represented the largest loss-of-exclusivity opportunity in history – valued at roughly $17bn in terms of brand sales.
Despite the excitement around the launches – which saw Amgen compete with the first US biosimilar in January 2023, followed...



![[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space](https://web.insights.norstella-labs.com/resizer/v2/G3M6E2FVDNOJPCEXELJNOIKH64.jpg?smart=true&auth=b5d5c6477bcbd6c122699f47191cbafe560695783f500a6e7b10c4d270965bdc&width=400&height=225)
